ICER deems hemophilia gene therapies worth the $2.5M price tagR&D, TherapeuticsThe Institute for Clinical and Economic Review (ICER) concluded Tuesday that gene therapies for hemophilia A and B are worth it even at a hefty lifetime cost of $2.5 million. Read more September 15, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/09/BioSpaceHemophilia9-15-2022.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-09-15 10:00:462022-09-15 12:54:40ICER deems hemophilia gene therapies worth the $2.5M price tag
